You are here > News and publications

News and publications

Promethera Biosciences reshapes its leadership team


Mont-Saint-Guibert, Belgium, January 23, 2015 - Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of inborn errors of metabolism and acquired liver diseases, today announces the resignation of Eric Halioua from his post as CEO of Promethera and all other functions within the company. He has decided to leave in order to concentrate on other projects.


Download this file (FR)

Download this file (EN)


PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea